Targets › CSF3R
15 programs from 15 companies in 39 trials: 21 Phase 2, 11 Phase 3, 4 Phase 1, 3 Phase 4; Oncology, Hematology, Other; next expected readout Nov 2026.
Receptor for granulocyte colony-stimulating factor (CSF3), essential for granulocytic maturation. Plays a crucial role in the proliferation, differentiation and survival of cells along the neutrophilic lineage. (UniProt, Q99062)
Open in Phaseline: the race on CSF3R, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| The First Affiliated Hospital with Nanjing Medical University | PEG-rhG-GSF Granulocyte colony-stimulating factor (pegylated) | CSF3R | Phase 3 | Esophageal Squamous Cell Carcinoma | Nov 2026 |
| Savara | Regramostim Granulocyte colony stimulating factor receptor agonist | CSF3R | Phase 3 | Autoimmune Pulmonary Alveolar Proteinosis | May 2027 |
| Kexing Biopharm | Pegfilgrastim Granulocyte colony stimulating factor receptor agonist | CSF3R | Phase 3 | Neutropenia, Chemotherapy-Induced Febrile; Non-Hodgkin's Lymphoma; Multiple Myeloma; Esophageal Cancer … | – |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Mecapegfilgrastim Long-acting recombinant human granulocyte colony-stimulating factor (rhG-CSF) | CSF3R | Phase 2 | Metastatic Breast Cancer | Dec 2026 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Telpegfilgrastim Injection PEGylated recombinant human granulocyte colony-stimulating factor (pegylated rhG-CSF) | CSF3R | Phase 2 | Solid Tumors | Apr 2027 |
| Qilu Pharmaceutical | QLC2519 Modified G-CSF fused to human serum albumin (HSA) with reduced G-CSF receptor affinity | CSF3R | Phase 2 | Pediatric Malignant Solid Tumor | Jun 2027 |
| Spectrum Pharmaceuticals | Eflapegrastim Granulocyte colony stimulating factor receptor agonist | CSF3R | Phase 2 | Solid Tumors | Oct 2027 |
| Affiliated Hospital of Nantong University | Mecapegfilgrastim injection Long-acting granulocyte colony-stimulating factor (G-CSF) analog; pegylated filgrastim | CSF3R | Phase 2 | Myelosuppression | Dec 2027 |
| CSL Behring | Anumigilimab (CSL324) Granulocyte colony stimulating factor receptor antagonist | CSF3R | Phase 2 | Sickle Cell Disease | Aug 2028 |
| Yaqrit | Filgrastim Granulocyte colony stimulating factor receptor agonist | CSF3R | Phase 2 | Acute-On-Chronic Liver Failure; Early-stage Breast Cancer; Diminished Ovarian Reserve; Allogeneic Granulocyte Donation … | Aug 2028 |
| Institute of Hematology & Blood Diseases Hospital, China | Mecapegfilgrastim Long-acting G-CSF receptor agonist | CSF3R | Phase 2 | Multiple Myeloma | – |
| IRCCS San Raffaele | Myelostim (G-CSF) Granulocyte-colony stimulating factor receptor agonist | CSF3R | Phase 2 | Chronic Granulomatous Disease X-linked (X-CGD) | – |
| Sun Yat-sen University | Telpegfilgrastim Long-acting G-CSF receptor agonist | CSF3R | Phase 2 | Chemotherapy-Induced Neutropenia | – |
| National Cancer Center, Korea | Tripegfilgrastim G-CSF receptor agonist (pegylated G-CSF analog) | CSF3R | Phase 2 | Unresectable Pancreatic Cancer | – |
| Nanjing King-Friend Biochemical Pharmaceutical | NKF-PEG Pegfilgrastim biosimilar; granulocyte colony-stimulating factor (G-CSF) analog | CSF3R | Phase 1 | Healthy Participants | Nov 2026 |
Solid Tumors (2) Autoimmune Pulmonary Alveolar Proteinosis (2) Multiple Myeloma (2) Non-Hodgkin's Lymphoma (2) Aplastic Anemia (2) Unresectable Pancreatic Cancer (1) Healthy Participants (1) Sickle Cell Disease (1) Myelosuppression (1) Esophageal Squamous Cell Carcinoma (1) Chronic Granulomatous Disease X-linked (X-CGD) (1) Pediatric Malignant Solid Tumor (1)
protein or peptide (6), small molecule (4), mixed (4), antibody (1)
National Cancer Center, Korea (1) Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) Nanjing King-Friend Biochemical Pharmaceutical (1) CSL Behring (1) Savara (1) Affiliated Hospital of Nantong University (1) The First Affiliated Hospital with Nanjing Medical University (1) Institute of Hematology & Blood Diseases Hospital, China (1) Spectrum Pharmaceuticals (1) IRCCS San Raffaele (1) Qilu Pharmaceutical (1) Kexing Biopharm (1) Yaqrit (1) Sun Yat-sen University (1) Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.